STRONG SALES AND EARNINGS INCREASE IN THE FIRST HALF-YEAR 2024

Donaueschingen, 13/08/2024: Nexus AG, one of the leading European suppliers of software solutions in the healthcare sector, was able to increase its sales by approx. 14% and EBIT by approx. 18% in the first six months of 2024. As a result, the continually positive development of sales and earnings of the last years could be continued.

Sales improved from KEUR 111,842 to KEUR 127,665 (+14.2%) in the first half-year 2024. The international share of total business volume was 44.1% (6M-2023: 47.9%) and amounted to KEUR 56,233 compared to KEUR 53,516 (6M-2023).

The consolidated earnings before taxes (EBT) increased by 15.0% to KEUR 16,935 (6M-2023: KEUR 14,729), and consolidated surplus rose by 15.4% to KEUR 12,382 (6M-2023:
10,734 KEUR). EBIT rose very sharply by 18.2% from KEUR 13,888 (6M-2023) to KEUR 16,410, and EBITDA increased by 14.2% to KEUR 25,448 (6M-2023: KEUR 22,276).

Operating cash increased by 8.5% to KEUR 27,611 in the first six months (6M-2023: KEUR 25,460). As of 30/06/2024, the company had cash resources at its disposal in the amount of KEUR 108,034 (31/12/2023: KEUR 97,434). Excluding the companies acquired in the second half of 2023, the increase in sales would have been 9.4% and the increase in EBIT would have been 20.9%. KEUR 1,508 was spent on the integration of the acquired companies in the first half of 2024, which was recognised in earnings.

Nexus AG had equity capital amounting to KEUR 262,210 as of 30/06/2024 (31/12/2023: KEUR 258,582). Consequently, the equity capital rate is 61.9% (31/12/2023: 62.8%). This demonstrates that Nexus AG has a sustainable and healthy balance sheet as well as sufficient capital for further financing of its European growth strategy.

You might also be interested in

    • NEXUS-Gruppe

    VERY STRONG REVENUES AND EARNINGS INCREASE IN 2022

    Donaueschingen, 07/03/2023: Nexus AG, one of the leading European suppliers of software solutions in the healthcare sector, was able to increase its revenues by 11.1% and EBIT by 15.2% in the fiscal year 2022. As a result, the continually positive development of revenues and earnings of the last two decades could be continued.

    • NEXUS-Gruppe

    Strong sales and earnings increase in the first half-year 2023

    Donaueschingen, 15 August 2023: Nexus AG, one of the leading European suppliers of software solutions in the healthcare sector, was able to increase its sales by approx. 12% and EBT by 23% in the first six months of 2023. As a result, the continually positive development of sales and earnings of the last years could be continued.

    • NEXUS-Gruppe

    VERY STRONG SALES AND EARNINGS INCREASE IN THE FIRST QUARTER 2023

    Donaueschingen, 16/05/2023: Nexus AG, one of the leading European suppliers of software solutions in the healthcare sector, was able to increase its sales by 11% and EBIT by approx. 28% in the first three months of 2023. As a result, the continually positive development of sales and earnings of the last years could be continued.

    • NEXUS-Gruppe

    Very strong sales and earnings increase in the third quarter 2023

    Donaueschingen, 07/11/2023: Nexus AG, one of the leading European suppliers of software solutions in the healthcare sector, was able to increase its sales by 14% and EBT by approx. 33% in the first nine months of 2023. As a result, the continually positive development of sales and earnings of the last years could be continued.

    • NEXUS-Gruppe

    VERY STRONG REVENUES AND EARNINGS INCREASE IN 2023

    Donaueschingen, 05/03/2024: Nexus AG, one of the leading European suppliers of software solutions in the healthcare sector, was able to increase its revenues by 15.5% and EBT by 21% in the fiscal year 2023. As a result, the continually positive development of revenues and earnings of the last two decades could be continued.

Do you need help? We are happy to advise you.
Contact Mail
X
Version: 02148-001
Lightbulb
What are you looking for? Fachbereiche, Experten, Behandlungsschwerpunkte und Standorte
Nicht das gewünschte Ergebnis? Nutzen Sie die globale Suche. Zur Suche